| Filed On | Filing |
|---|---|
| 05 Feb 2024 |
8-K/A: Financial Statements and Exhibits
On November 17, 2023 (the “Closing Date”), Zevra Therapeutics, Inc., a Delaware corporation (“Zevra” or the “Company”) completed the previously announced acquisition of Acer Therapeutics Inc., a Delaware corporation (“Acer”), pursuant to... |
| 24 Nov 2020 |
8-K/A: Other Events
IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline, Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH) |
| 30 Oct 2020 |
8-K/A: Results of Operations and Financial Condition
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET |
| 19 Jun 2020 |
8-K/A: Regulation FD Disclosure
Celebration, FL – June 18, 2020 – KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPh... |
| 23 May 2017 |
8-K/A: Results of Operations and Financial Condition
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET |
Loading...